Citations

Clear

903 citation(s) found for "Gordon, S".

Time‐Related Burden of Treatment With Parenterally Administered Complement Inhibitors: A Mixed Methods Observational Study Exploring Experiences among Patients With Paroxysmal Nocturnal Hemoglobinuria
Dingli, David , Broderick, Lynne , Rizio, Avery A. , Rucker, Sloan, LaGasse, Kaitlin , White, Michelle K. , Burton, Elise, Gordon, S., Yen, Glorian P., Paulose, Jincy, Geevarghese, Anumaxine, Lee, Soyon , Carty, Michelle K , Dingli, David , Gordon, Shaquilla, Geevarghese, Anumaxine Lincy

Mayo Clinic

Health Science Reports | June 20, 2026 | Volume: 9 | Issue: 6 | Pages: No page available

10.1002/hsr2.72585 | PMID 42327465 Get It

Development of a Computed Tomography Enterography-Based Radiomics Model to Characterize Inflammation, Fibrosis, and Smooth Muscle Thickening in Stricturing Crohn's Disease
Sleiman, Joseph , Pillai, Gargi V. , Chirra, Prathyush , Gandhi, Namita , Gordon, Ilyssa O. , Hariri, Mohsen , Baker, Mark E. , Ream, Justin , Fulmer, Clifton G. , Ouali, Sara El , Bruining, David H., Rieder, Florian, Gandhi, Namita S , Fulmer, Clifton , El Ouali, Sara , Kurowski, Jacob A , Viswanath, Satish E , Sleiman, Joseph , Gordon, Ilyssa O , Baker, Mark E , Bruining, David H. , Rieder, Florian

Mayo Clinic

American Journal of Gastroenterology | June 9, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.14309/ajg.0000000000004073 | PMID 42262346 Get It

INTRODUCTION: Computed tomography enterography (CTE) is a noninvasive cross-sectional imaging modality routinely used for diagnosis of Crohn's disease (CD) strictures. However, CTE is limited in individually defining the severity of inflammation, fibrosis, or smooth muscle hyperplasia/hypertrophy (SMH) within such strictures. We developed and internally validated a radiomics-based machine learning model for separately characterizing the degree of histopathological inflammation, fibrosis, and SMH in CD strictures and compared it with centrally read visual radiologist scoring of CTE. METHODS: This single-center, cross-sectional study included 100 patients with CD (n = 66 for discovery; n = 34 for validation) with terminal ileal strictures confirmed on diagnostic CTE within 15 weeks of intestinal resection. Histopathological specimens were scored for inflammation, fibrosis, and SMH and spatially linked with corresponding pre-surgical CTE sequences. Annotated stricture regions on CTE were scored visually by radiologists as well as underwent three-dimensional radiomics-based machine-learning analysis; both evaluated against histopathology scoring. RESULTS: Three distinct sets of radiomic features capturing textural heterogeneity within strictures were separately linked with severe inflammation, fibrosis, and SMH across both discovery (accuracy = 0.74, 0.71, 0.71, respectively) and validation (accuracy = 0.74, 0.68, 0.68, respectively) cohorts. Radiologist visual scoring was limited, with accuracy of 0.51 for identifying severe inflammation, 0.48 for severe fibrosis, and 0.58 for severe SMH. Augmenting radiologist scoring with radiomic features yielded improved performance in identifying severe inflammation, fibrosis, or SMH compared to radiologist scoring alone. DISCUSSION: Radiomic features of CD strictures on CTE can identify severe histopathological fibrosis, inflammation, and smooth muscle hyperplasia and perform better than radiologist visual scoring in stricture characterization.
Scar-specific outcomes following minimally invasive versus conventional median sternotomy in cardiac surgery: A systematic review and meta-analysis
Chhatwal, Karanjot , Siu, Anthony On Chun, Arab, Sammy , Shah, Aishwarya , Rad, Arian Arjomandi , Chong, Gordon Lap Wai , Showkat, Monjur, Punjabi, Sangeeta, Punjabi, Prakash, Punjabi, Prakash P , Arjomandi Rad, Arian , Chong, Gordon Lap Wai , Arab, Sammy , Salih, Ahmed M. , Punjabi, Sangeeta

Mayo Clinic

Perfusion | June 9, 2026 | Volume: 41 | Issue: 6 | Pages: 814-828

10.1177/02676591261452059 | PMID 42261745 Get It

Background With improved cardiac surgical outcomes, attention has shifted to patient-centred outcomes, including cosmetic appearances of surgical scars. Minimally invasive cardiac surgery (MICS) is often promoted for its cosmetic benefits, yet empirical evidence remains limited. This study aimed to systematically evaluate scar-specific outcomes comparing MICS to conventional full median sternotomy (FMS) in adult cardiac surgery. Methods A systematic review and meta-analysis was conducted following PRISMA guidelines. PubMed, Embase, Central, and Scopus were searched from inception to August 2025. Studies comparing MICS to FMS, reporting scar-related patient-reported outcomes, wound complications, or cosmetic satisfaction, were included. The primary outcome was scar assessment using validated instruments. Random-effects models calculated standardised mean differences (SMD) and risk ratios (RR) with 95% confidence intervals. Results Twenty-two studies comprising 3131 patients (1459 MICS, 1672 FMS) met inclusion criteria. MICS demonstrated significantly better scar assessment scores (SMD −0.74, 95% CI −1.27 to −0.22; p < 0.01; I 2 = 88%, six studies), higher patient satisfaction rates (RR 1.42, 95% CI 1.21–1.66; p < 0.001; I 2 = 84%, 12 studies), and reduced wound complications (RR 0.31, 95% CI 0.20–0.47; p < 0.001; I 2 = 0%, nine studies). Only six studies reported validated scar assessment scores, highlighting limited integration of these measures. Substantial heterogeneity was observed due to diverse assessment tools and surgical techniques. Conclusions MICS can offer significant advantages in scar-specific outcomes compared to FMS in carefully selected patient populations. Cosmetic outcomes should be interpreted within the context of overall effectiveness and may support shared decision making only when clinical outcomes between surgical approaches are comparable. The lack of standardised scar assessment protocols and limited reporting of cosmetic outcomes represent critical gaps. Future research should prioritise standardised scar evaluation tools and expand cosmetic outcome reporting across all cardiac surgical procedures.
Safety and efficacy results of the phase 2 study of silevertinib (BDTX-1535) in treatment-naïve patients with non-small cell lung cancer with non-classical EGFR mutations.
Rotow, Julia K., Baik, Christina S., Dimou, Anastasios, Feng, Jamie, Gordon, Sarah , Chen, Haobin , Desai, Aakash, Niu, Jiaxin, Benyounes, Amin, Sankar, Kamya, Spira, A.I., Stevenson, James, Patel, Shetal , Halmos, Balazs, Shu, Catherine A., Le, Xiuning, Baik, Christina S. , Dimou, Anastasios , Nguyen, Danny , Niu, Jiaxin , Johnson, Melissa L. , Sankar, K. Nathan , Scott, Susan Combs , Stevenson, James, Halmos, Balazs , Shu, Catherine A. , Yu, Helena Alexandra , Le, Xiuning

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 8519-8519

10.1200/jco.2026.44.16_suppl.8519 Get It

8519 Background: Non-classical mutations (NCM) of epidermal growth factor receptor (EGFR) represent a broad group of oncogenic mutations in non-small cell lung cancer (NSCLC), often associated with resistance to osimertinib (e.g., P-loop and αC-helix compressing [PACC] mutations). Patients (pts) with NCM have inferior clinical outcomes with a high incidence of CNS metastases (CNSm). Silevertinib (BDTX-1535) is a fourth-generation, covalent EGFR TKI with high CNS penetrance targeting both EGFR classical mutations and NCM. The antitumor activity and safety of silevertinib in pts with advanced NSCLC were evaluated in a Phase 2 trial (NCT05256290). Methods: Pts with advanced EGFR NCM NSCLC who received no prior systemic therapy were enrolled (Cohort 3) based on a local molecular test. Silevertinib 200 mg was administered orally once daily. The primary endpoint of objective response rate (ORR) was assessed using RECIST v1.1. CNS ORR was assessed using Response Assessment in Neuro-Oncology for Brain Metastases (RANO-BM) in pts with no prior CNS therapy. Secondary endpoints include progression-free survival (PFS), duration of response (DOR), disease control rate (DCR), and safety. Results: From February 2024 to July 2025, 43 pts with 35 unique NCMs (including 25 pts with PACC mutations) were enrolled in Cohort 3: median age 70.0 years, 72% female, 74% white, and 42% never smoked cigarettes. As of November 3, 2025, median follow-up was 7.2 months. ORR by RECIST v1.1 is shown in the table. Sixteen pts (37%) had CNSm, including 7 pts (16%) with measurable CNS disease. RANO-BM CNS response was 86% (n=6/7). Complete clearance of EGFR VAF ctDNA was observed in 21/26 (81%) evaluable pts. Serious treatment-related adverse events (TRAEs) were reported in 5 pts (12%), and 4 pts (9%) discontinued treatment due to TRAEs. The most common TRAEs included rash (19%, grade 3), diarrhea (19%, grade 3), stomatitis (9%, grade 3), and paronychia (5%, grade 3). While 77% of pts had a dose reduction, 19/22 (86%) patients with a radiographic response maintained or deepened their response after dose reduction, including all patients with CNS response. Conclusions: Silevertinib demonstrated robust antitumor activity in treatment-naïve pts with a broad spectrum of NCM EGFR driver mutations with high intracranial activity in pts with brain metastases. The safety profile was consistent with the known AEs of the EGFR TKI class. Clinical trial information: NCT05256290 . Data as of November 3, 2025 N ORR n (%) 95% CI DCR n (%) 95% CI ITT Population * 43 26 (60) (44.4, 75.0) 39 (91) (77.9, 97.4) PACC mutations 25 14 (56) (34.9, 75.6) 22 (88) (68.8, 97.5) Compound mutations † 16 11 (69) (41.3, 89.0) 15 (94) (69.8, 99.8) *No pts with classical (E746_A750del or L858R) mutations were enrolled. † Presence of ≥ 2 NCMs. As of December 27, 2025, the 6-month PFS rate was 86% overall and 80% in pts with CNSm; available PFS and DOR data will be presented.
Decompression with or without Duraplasty for Chiari I and Syringomyelia
Limbrick, David D. , Shannon, Chevis N., Bayman, Emine O., Meehan, Thanda, Kallem, Marisa, Ackerman, Laurie L. , Adelson, P. David , Albert, Gregory, Aldana, Philipp R. , Alden, Tord D. , Anderson, Richard C. E. , Baird, Lissa C., Bauer, David, Bethel-Anderson, Tammy, Bierbrauer, Karin, Brockmeyer, Douglas L. , Chern, Joshua J. , Couture, Daniel, Daniels, David J., Dauser, Robert C., Durham, Susan, Ellenbogen, Richard G., Eskandari, Ramin, Gannon, Stephen R., Grant, Gerald A., Greene, Stephanie, Gross, Naina L. , Guillaume, Daniel J. (Daniel James), Hankinson, T., Heuer, Gregory, Iantosca, Mark, Iskandar, Bermans J. , Jackson, Eric M., Keating, Robert F., Kelly, Michael P., Kennedy, Elaine, Krieger, Mark D., Kulkarni, Abhaya V., Labuda, Rick, Leonard, Jeffrey R., Maher, Cormac O. , Mangano, Francesco T. , McComb, J. Gordon, McEvoy, Sean D., Niazi, Toba N., Oakes, Jerry, Olavarria, Greg, O’Neill, Brent R., Poppe, Dorothy, Ragheb, John, Reynolds, Lisa, Selden, Nathan R., Shah, Manish N., Smyth, Matthew D., Spears, Sandy, Stone, Scellig , Strahle, Jennifer M., Tamber, M, Tramelli, Gina, Tuite, Gerald F. , Vance, Haley, Wait, Scott D. , Wellons, John C. , Whitehead, WE, Yahanda, Alexander T., Yan, Yan, Dacey, Ralph G. , Park, Tae Sung, Torner, James C., Kelly, Michael P. , Torner, James C. , Dlouhy, Brian J , Iskandar, Bermans J , Yahanda, Alexander T , Kelly, Michael P , Limbrick, David D. , Bayman, Emine O. , Ahmed, Raheel , Albert, Gregory W. , Bierbrauer, Karin S. , Daniels, David J. , Ellenbogen, Richard G., Graupman, Patrick C. , Greenberg, Jacob K , Greenfield, Jeffrey P. , Guillaume, Daniel, Iantosca, Mark, Jackson, Eric M., Jallo, George I. , Johnston, James M. , Keating, Robert F., Kennedy, Elaine, Kulkarni, Abhaya V. , McComb, J. Gordon , McKinstry, Robert C. , Menezes, Arnold H. , Poppe, Dorothy , Ragheb, John , Reeves, Samuel, Reynolds, Lisa, Selden, Nathan R. W. , Shah, Manish N. , Shimony, Joshua S. , Strahle, Jennifer M. , Tamber, Mandeep S. , Tyler‐Kabara, Elizabeth C. , Vance, E. Haley, Yahanda, Alexander T. , Park, Tae Sung

Mayo Clinic

New England Journal of Medicine | May 27, 2026 | Volume: 394 | Issue: 20 | Pages: 2015-2025

10.1056/nejmoa2402821 | PMID 42202320 Get It

Mohs Surgery from 2016 to 2022: Declining Medicaid Reimbursement and ACA Expansion Impact
Verhey, Britta E., Holle, Alejandro M, Aframian, Kimiya R. , Saylor, Drew K. , Bae, Gordon H., Holle, Alejandro M. , Bae, Gordon Hyeonjin

Mayo Clinic

No container title available | May 26, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-9261181/v1 Get It

Abstract Mohs Surgery from 2016 to 2022: Declining Medicaid Reimbursement and ACA Expansion Impact Mohs micrographic surgery (MMS) is the standard of care for many nonmelanoma skin cancers, yet access remains highly variable due to low reimbursement rates. Only 39.5% of Mohs surgeons nationally accept Medicaid. While the Affordable Care Act (ACA) Medicaid expansion improved coverage for low-income adults, its effects on dermatologic reimbursement remain unclear. This study provides the first comprehensive analysis of inflation-adjusted Medicaid reimbursement trends for MMS and determines whether ACA Medicaid expansion translated into improved payment rates. Average physician reimbursement per patient for MMS procedures (CPT codes 17311–17314) from 2016 to 2022 was extracted from a large insurance claims database and adjusted for inflation to 2022 U.S. dollars. States were categorized by Medicaid expansion status, and linear regression assessed reimbursement trends. Between 2016 and 2022, national weighted average reimbursement for MMS first stage (CPT 17311) declined 18.33%, while MMS additional stages (CPT 17312) decreased 25.52% (p = 0.0182). When stratified by expansion status, CPT 17311 reimbursement declined − 5.71% in expansion states versus increasing + 5.80% in non-expansion states (p = 0.00121). Reimbursement for non-high-risk anatomic areas declined 26.10% and 32.6%, respectively. Inflation-adjusted Medicaid payments for MMS declined substantially from 2016 to 2022, with greater reductions in Medicaid expansion states. While ACA expansion increased coverage, it introduced financial pressures through lower fee schedules, potentially threatening physician participation and access to essential dermatologic surgery for vulnerable populations.